The responsiveness of goal attainment scaling using just one goal in controlled clinical trials: an exploratory analysis.
Assessment
Dementia
Frailty
Goal attainment
RCT
Responsiveness
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
12 May 2020
12 May 2020
Historique:
received:
18
06
2019
accepted:
13
04
2020
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
14
5
2020
Statut:
epublish
Résumé
Goal Attainment Scaling (GAS) is an individualized outcome measure that allows the setting of personalized treatment goals. We compared the responsiveness of GAS when individuals set only one goal instead of the recommended three or more goals. We conducted exploratory analyses on data from two randomized controlled trials: the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) (n = 130); and the Mobile Geriatric Assessment Team (MGAT) (n = 265). Independent t-tests and standardized response means (SRMs) were used to assess responsiveness of one- vs. multiple-goal GAS. In VISTA, clinician-rated multiple-goal GAS detected higher goal attainment in the intervention group (p = 0.01; SRM = 0.48). One-goal GAS, whether rated by patients or by clinicians, did not detect differences in goal attainment between groups (patient: p = 0.56, SRM = 0.10; clinician: p = 0.10, SRM = 0.29). In MGAT, multiple-goal GAS (outcome goals: p < .001, SRM = 1.29; total goals: p < .001, SRM = 1.52) and one-goal GAS (outcome goals: p < .001, SRM = 0.89; total goals: p < .001, SRM = 0.75), detected significantly higher goal attainment in the intervention group. One-goal GAS detected significant change in response to a patient-centred, multi-domain care initiative. As such, in similar contexts, one-goal GAS may be an effective means of optimizing personalization and improving GAS feasibility through reduced administration time. However, it is not yet clear if one-goal GAS is responsive in the context of a pharmacological intervention and further research is recommended.
Sections du résumé
BACKGROUND
BACKGROUND
Goal Attainment Scaling (GAS) is an individualized outcome measure that allows the setting of personalized treatment goals. We compared the responsiveness of GAS when individuals set only one goal instead of the recommended three or more goals.
METHODS
METHODS
We conducted exploratory analyses on data from two randomized controlled trials: the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) (n = 130); and the Mobile Geriatric Assessment Team (MGAT) (n = 265). Independent t-tests and standardized response means (SRMs) were used to assess responsiveness of one- vs. multiple-goal GAS.
RESULTS
RESULTS
In VISTA, clinician-rated multiple-goal GAS detected higher goal attainment in the intervention group (p = 0.01; SRM = 0.48). One-goal GAS, whether rated by patients or by clinicians, did not detect differences in goal attainment between groups (patient: p = 0.56, SRM = 0.10; clinician: p = 0.10, SRM = 0.29). In MGAT, multiple-goal GAS (outcome goals: p < .001, SRM = 1.29; total goals: p < .001, SRM = 1.52) and one-goal GAS (outcome goals: p < .001, SRM = 0.89; total goals: p < .001, SRM = 0.75), detected significantly higher goal attainment in the intervention group.
CONCLUSION
CONCLUSIONS
One-goal GAS detected significant change in response to a patient-centred, multi-domain care initiative. As such, in similar contexts, one-goal GAS may be an effective means of optimizing personalization and improving GAS feasibility through reduced administration time. However, it is not yet clear if one-goal GAS is responsive in the context of a pharmacological intervention and further research is recommended.
Identifiants
pubmed: 32399731
doi: 10.1186/s41687-020-00196-8
pii: 10.1186/s41687-020-00196-8
pmc: PMC7218040
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Subventions
Organisme : Mitacs
ID : IT09427
Références
J Frailty Aging. 2017;6(1):37-45
pubmed: 28244557
J Gerontol A Biol Sci Med Sci. 1999 Dec;54(12):M641-7
pubmed: 10647971
Community Ment Health J. 1968 Dec;4(6):443-53
pubmed: 24185570
J Clin Epidemiol. 2003 Aug;56(8):736-43
pubmed: 12954465
J Clin Epidemiol. 1993 Oct;46(10):1113-8
pubmed: 8410096
Qual Life Res. 2017 Mar;26(3):685-693
pubmed: 28000094
Neuroepidemiology. 1996;15(6):330-8
pubmed: 8930946
Haemophilia. 2018 Jul;24(4):e199-e206
pubmed: 29626387
J Am Geriatr Soc. 2000 Sep;48(9):1080-5
pubmed: 10983907
J Rehabil Med. 2009 Jun;41(7):528-35
pubmed: 19543663
J Am Geriatr Soc. 2018 Nov;66(11):2120-2127
pubmed: 30298901
Arch Phys Med Rehabil. 2008 Apr;89(4):652-9
pubmed: 18373995
J Patient Rep Outcomes. 2019 Apr 1;3(1):20
pubmed: 30931491
Med Care. 1990 Jul;28(7):632-42
pubmed: 2366602
N Engl J Med. 2012 Mar 1;366(9):777-9
pubmed: 22375966
Clin Rehabil. 2011 Dec;25(12):1128-39
pubmed: 21795404
CMAJ. 2006 Apr 11;174(8):1099-105
pubmed: 16554498
Clin Pharmacol Ther. 2010 Oct;88(4):446-9
pubmed: 20856240
Gerontologist. 1998 Dec;38(6):735-42
pubmed: 9868853